메뉴 건너뛰기




Volumn 20, Issue 1, 2018, Pages

Effectiveness and safety of tofacitinib in rheumatoid arthritis: A cohort study

Author keywords

Biologic therapy; Comparative effectiveness research; Disease modifying antirheumatic drug; Rheumatoid arthritis; Tofacitinib

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

EID: 85044268290     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-018-1539-6     Document Type: Article
Times cited : (49)

References (28)
  • 2
    • 85019702082 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
    • Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960-77.
    • (2017) Ann Rheum Dis , vol.76 , Issue.6 , pp. 960-977
    • Smolen, J.S.1    Landewé, R.2    Bijlsma, J.3    Burmester, G.4    Chatzidionysiou, K.5    Dougados, M.6
  • 3
    • 84930323836 scopus 로고    scopus 로고
    • Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis
    • Buckley F, Finckh A, Huizinga TW, Dejonckheere F, Jansen JP. Comparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysis. J Manag Care Spec Pharm. 2015;21(5):409-23.
    • (2015) J Manag Care Spec Pharm , vol.21 , Issue.5 , pp. 409-423
    • Buckley, F.1    Finckh, A.2    Huizinga, T.W.3    Dejonckheere, F.4    Jansen, J.P.5
  • 4
    • 85006699538 scopus 로고    scopus 로고
    • Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database
    • Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. administrative claims database. J Manag Care Spec Pharm. 2016;22(12):1457-71.
    • (2016) J Manag Care Spec Pharm , vol.22 , Issue.12 , pp. 1457-1471
    • Harnett, J.1    Gerber, R.2    Gruben, D.3    Koenig, A.S.4    Chen, C.5
  • 6
    • 84924842188 scopus 로고    scopus 로고
    • Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
    • Souto A, Maneiro JR, Salgado E, Carmona L, Gomez-Reino JJ. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford). 2014;53(10):1872-85.
    • (2014) Rheumatology (Oxford) , vol.53 , Issue.10 , pp. 1872-1885
    • Souto, A.1    Maneiro, J.R.2    Salgado, E.3    Carmona, L.4    Gomez-Reino, J.J.5
  • 7
    • 84965060726 scopus 로고    scopus 로고
    • Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
    • Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75(10):1843-7.
    • (2016) Ann Rheum Dis , vol.75 , Issue.10 , pp. 1843-1847
    • Curtis, J.R.1    Xie, F.2    Yun, H.3    Bernatsky, S.4    Winthrop, K.L.5
  • 8
    • 85029457249 scopus 로고    scopus 로고
    • Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making
    • Berger ML, Sox H, Willke RJ, Brixner DL, Eichler HG, Goettsch W, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Pharmacoepidemiol Drug Saf. 2017;26(9):1033-9.
    • (2017) Pharmacoepidemiol Drug Saf , vol.26 , Issue.9 , pp. 1033-1039
    • Berger, M.L.1    Sox, H.2    Willke, R.J.3    Brixner, D.L.4    Eichler, H.G.5    Goettsch, W.6
  • 9
    • 84858645799 scopus 로고    scopus 로고
    • Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report
    • Berger ML, Dreyer N, Anderson F, Towse A, Sedrakyan A, Normand SL. Prospective observational studies to assess comparative effectiveness: the ISPOR good research practices task force report. Value Health. 2012;15(2):217-30.
    • (2012) Value Health , vol.15 , Issue.2 , pp. 217-230
    • Berger, M.L.1    Dreyer, N.2    Anderson, F.3    Towse, A.4    Sedrakyan, A.5    Normand, S.L.6
  • 11
    • 77958121473 scopus 로고    scopus 로고
    • Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database
    • Petri H, Maldonato D, Robinson NJ. Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database. BMC Musculoskelet Disord. 2010;11:247.
    • (2010) BMC Musculoskelet Disord , vol.11 , pp. 247
    • Petri, H.1    Maldonato, D.2    Robinson, N.J.3
  • 12
    • 84904791286 scopus 로고    scopus 로고
    • Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims
    • Curtis JR, Schabert VF, Harrison DJ, Yeaw J, Korn JR, Quach C, et al. Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims. Clin Ther. 2014;36(7):996-1004.
    • (2014) Clin Ther , vol.36 , Issue.7 , pp. 996-1004
    • Curtis, J.R.1    Schabert, V.F.2    Harrison, D.J.3    Yeaw, J.4    Korn, J.R.5    Quach, C.6
  • 14
    • 84929078493 scopus 로고    scopus 로고
    • Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis
    • Bonafede M, Johnson BH, Princic N, Shah N, Harrison DJ. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis. J Med Econ. 2015;18(5):376-89.
    • (2015) J Med Econ , vol.18 , Issue.5 , pp. 376-389
    • Bonafede, M.1    Johnson, B.H.2    Princic, N.3    Shah, N.4    Harrison, D.J.5
  • 15
    • 80053174347 scopus 로고    scopus 로고
    • Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis
    • Curtis JR, Baddley JW, Yang S, Patkar N, Chen L, Delzell E, et al. Derivation and preliminary validation of an administrative claims-based algorithm for the effectiveness of medications for rheumatoid arthritis. Arthritis Res Ther. 2011;13(5):R155.
    • (2011) Arthritis Res Ther , vol.13 , Issue.5 , pp. R155
    • Curtis, J.R.1    Baddley, J.W.2    Yang, S.3    Patkar, N.4    Chen, L.5    Delzell, E.6
  • 20
    • 84929087628 scopus 로고    scopus 로고
    • Princeton, NJ: Bristol-Myers Squibb Company.
    • Bristol-Myers Squibb Company. Orencia (abatacept) prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2014.
    • (2014) Orencia (abatacept) prescribing information
  • 21
    • 0004879274 scopus 로고    scopus 로고
    • Malvern, PA: Centocor Ortho Biotech, Inc.
    • Centocor Ortho Biotech, Inc. Remicade (infliximab) prescribing information. Malvern, PA: Centocor Ortho Biotech, Inc.; 2013.
    • (2013) Remicade (infliximab) prescribing information
  • 22
    • 85013878103 scopus 로고    scopus 로고
    • South San Francisco, CA: Biogen/Genentech USA, Inc.
    • Biogen/Genentech USA, Inc. Rituxan (rituximab) prescribing information. South San Francisco, CA: Biogen/Genentech USA, Inc.; 2016.
    • (2016) Rituxan (rituximab) prescribing information
  • 24
    • 34848839939 scopus 로고    scopus 로고
    • Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies
    • Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, British Society for Rheumatology Biologics Register Control Centre Consortium, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56(9):2896-904.
    • (2007) Arthritis Rheum , vol.56 , Issue.9 , pp. 2896-2904
    • Dixon, W.G.1    Symmons, D.P.2    Lunt, M.3    Watson, K.D.4    Hyrich, K.L.5
  • 25
    • 84903483215 scopus 로고    scopus 로고
    • Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis
    • Curtis JR, Yang S, Patkar NM, Chen L, Singh JA, Cannon GW, et al. Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(7):990-7.
    • (2014) Arthritis Care Res (Hoboken) , vol.66 , Issue.7 , pp. 990-997
    • Curtis, J.R.1    Yang, S.2    Patkar, N.M.3    Chen, L.4    Singh, J.A.5    Cannon, G.W.6
  • 26
    • 85006819043 scopus 로고    scopus 로고
    • Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis
    • Kawashima H, Kagami SI, Kashiwakuma D, Takahashi K, Yokota M, Furuta S, et al. Long-term use of biologic agents does not increase the risk of serious infections in elderly patients with rheumatoid arthritis. Rheumatol Int. 2017;37(3):369-76.
    • (2017) Rheumatol Int , vol.37 , Issue.3 , pp. 369-376
    • Kawashima, H.1    Kagami, S.I.2    Kashiwakuma, D.3    Takahashi, K.4    Yokota, M.5    Furuta, S.6
  • 27
    • 84904818200 scopus 로고    scopus 로고
    • The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy
    • Kissin EY. The "dirty little secret" exposed in the 2013 EULAR recommendations for rheumatoid arthritis therapy. Clin Ther. 2014;36(7):1114-6.
    • (2014) Clin Ther , vol.36 , Issue.7 , pp. 1114-1116
    • Kissin, E.Y.1
  • 28
    • 79959790816 scopus 로고    scopus 로고
    • The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents
    • Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011;70(8):1401-6.
    • (2011) Ann Rheum Dis , vol.70 , Issue.8 , pp. 1401-1406
    • Curtis, J.R.1    Xie, F.2    Chen, L.3    Baddley, J.W.4    Beukelman, T.5    Saag, K.G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.